ICU Medical (NASDAQ:ICUI) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of ICU Medical (NASDAQ:ICUI) in a report issued on Wednesday,Benzinga reports.

ICUI has been the topic of a number of other reports. KeyCorp boosted their target price on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Jefferies Financial Group began coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price for the company. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Stock Down 1.8 %

ICUI opened at $174.81 on Wednesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The company has a market capitalization of $4.27 billion, a PE ratio of -38.25 and a beta of 0.66. The stock’s fifty day moving average is $176.11 and its 200-day moving average is $141.98. ICU Medical has a one year low of $82.82 and a one year high of $196.26.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.04%. The company had revenue of $580.07 million during the quarter, compared to the consensus estimate of $574.77 million. On average, equities analysts predict that ICU Medical will post 3.81 EPS for the current fiscal year.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,502 shares of company stock valued at $8,445,976. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ICUI. BNP Paribas Financial Markets lifted its holdings in shares of ICU Medical by 55.3% during the 1st quarter. BNP Paribas Financial Markets now owns 4,552 shares of the medical instruments supplier’s stock worth $489,000 after acquiring an additional 1,620 shares during the period. Texas Permanent School Fund Corp grew its position in ICU Medical by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,708 shares of the medical instruments supplier’s stock worth $1,900,000 after acquiring an additional 243 shares during the last quarter. Sei Investments Co. boosted its stake in ICU Medical by 52.1% in the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock worth $3,068,000 after purchasing an additional 9,793 shares in the last quarter. Russell Investments Group Ltd. lifted its position in ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares in the last quarter. Finally, US Bancorp DE raised its position in ICU Medical by 18.2% in the 1st quarter. US Bancorp DE now owns 3,098 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 476 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.